# Shaping the Future of HTA in Italy: Insights from the Italian Health Policy Forum

## TL;DR

Experts in Italy discussed how to implement new EU health technology rules, focusing on challenges and solutions for healthcare innovation.

## Contribution

The paper presents insights and recommendations from a forum on adapting the EU HTA Regulation in Italy, emphasizing collaboration and training.

## Key findings

- Two groups identified challenges in the EU HTA Regulation and proposed solutions for healthcare systems.
- Recommendations include promoting cooperation among countries and strengthening training for decision-makers.
- A monitoring system is suggested to evaluate the impact of the EU HTA Regulation.

## Abstract

The implementation of the European (EU) Health Technology Assessment (HTA) Regulation 2021/2282 (EU HTAR) offers many opportunities, aimed at harmonizing HTA procedures and improving access to innovations; it also represents a significant challenge for the European healthcare system. Within the 2024 Health Policy Forum Italy meeting, different actors, stakeholders, and institutions had the opportunity to discuss major criticism and opportunities coming from the EU-HTA Regulation addressing future developments in the healthcare sector. Two groups, EU & Italy Pharmaceuticals and EU-Italy Medical Devices, worked distinctively on the EU HTAR by highlighting key issues that may pose challenges at both European and national levels, proposing potential solutions. The allocation of participants into two groups, according to their affiliation with either the pharmaceutical or the medical device sector, enhances the diversity of professional backgrounds and institutional perspectives, thereby fostering a more comprehensive and informed discussion. The recommendations highlighted by the two groups emphasize the need to promote cooperation among Member States, strengthen training for decision-makers, and develop a monitoring system to evaluate EU HTA’s impact.